CBER Director Peter Marks says FDA plans to explore whether there is an intermediate pathway between tissue regulations and a full BLA for certain cellular products. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, Getty images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
